[ad_1]
DUBLIN, Aug. 8, 2022 /PRNewswire/ — The “Biopharmaceutical Excipients Market – Global Outlook and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.
The global biopharmaceutical excipients market is expected to grow at a CAGR of 7.56% during 2022-2027.
The constant shift of trends in the pharma sector, including new drug development, continuous manufacturing, and innovative drug technologies, has donated to a surge in demand for excipients with advanced functions. Between 40-70% of marketed drugs and up to 90% of all new chemical entities (NCEs) registered to suffer from poor water solubility. This can have significant negative consequences on the bioavailability of the active pharmaceutical ingredient (API), potentially impacting the therapeutic effect. The market for solubility-enhancing excipients and related technologies is proliferating to tackle the problem.
High-concentration biologic formulations account for an increasing percentage of the drug development pipeline as drug manufacturers seek to offer advanced therapeutics that the patient or caregiver can administer in the home setting. These high concentrations include protein-protein interactions due to higher viscosities. Excipients can help minimize these interactions without negatively impacting protein stability and other aspects of biologic formulations. This is driving a shift towards carefully selected combinations of viscosity-reducing excipients.
Biologics- Pipeline and Product Approvals, a Major driver for Biopharmaceutical Excipients Market
With a growing number of infectious diseases and cancers, there is a high demand for various biologic drugs. Innovative biopharmaceutical companies are continuously operating with stakeholders across the R&D landscape for the expansion of newer ways to treat such diseases. To date, 258 vaccines are in the pipeline for treating and preventing severe infectious diseases. According to a study, trends in global vaccine R&D found that the proportion of new vaccine candidates entering all stages of clinical …
Full story available on Benzinga.com
[ad_2]
Source link
